HVTN Spokespeople

Larry Corey, M.D.

Larry Corey, M.D., HIV Vaccine Trials Network
Larry Corey, M.D., Principal Investigator for the world's largest publicly funded collaboration facilitating the development of vaccines to prevent HIV/AIDS.

Lawrence Corey is past president of the Fred Hutchinson Cancer Research Center and a member of its Vaccine and Infectious Disease, Public Health Sciences and Clinical Research divisions. He is a professor of Medicine and Laboratory Medicine at the University of Washington, was head of the Virology Division at the University of Washington from 1978 to 2010, and led the AIDS Clinical Trials Group (ACTG) from 1987 to 1992. He has been Principal Investigator of the HVTN since its inception in 1999.

An internationally renowned expert in virology, viral immunology and vaccine development, Corey’s research has transformed the way we manage patients globally. With Nobel Laureate Dr. Gertrude Elion, he was the first to demonstrate that an antiviral compound, acyclovir, specific for a viral enzyme could be safely and effectively administered to control a chronic viral infection. These studies provided the foundation for the subsequent development of antiviral therapy for HIV and hepatitis viruses. Under his leadership at the ACTG, AZT was shown to reduce maternal fetal transmission; providing the impetus for the introduction of antiretrovirals to avert pediatric HIV infections internationally. He pioneered the use of viral load as predictors of clinical benefit and his studies demonstrating the early administration of combination antiretroviral therapy provided the strategy to reduce HIV morbidity and mortality globally. Corey’s work in HSV-2 established the framework for understanding the herpes pandemic and its role in HIV acquisition and progression.

Corey received his B.S. and M.D. from the University of Michigan and his infectious diseases training at the University of Washington. He is a member of the US National Academy of Medicine and the American Academy of Arts and Sciences, was the recipient of the Parran Award for his work in HSV-2, the American Society of Microbiology Cubist Award for his work on antivirals, and the University of Michigan Medical School Distinguished Alumnus Award. He is one of the most highly cited biomedical researchers in the last 20 years and is the author, coauthor or editor of over 1000 scientific publications.

Steve Wakefield

Wakefield is the External Relations Director for the HIV Vaccine Trials Network and leads global efforts for stakeholder engagement.

Steve Wakefield is the External Relations Director for the HIV Vaccine Trials Network and leads global efforts for stakeholder engagement. Wakefield (preferred name) is also founder of The Legacy Project, a program to increase racial and ethnic population involvement in trials. Wakefield currently serves on the AVAC: Global HIV Prevention Board and is an HIV-negative health care advocate with over thirty-five years of involvement in projects that increase community participation in HIV prevention research and ethics. A longtime human rights and HIV activist with nonprofit management, public service on Chicago’s Board of Health, as well as global and U.S. advisory groups such as WHO’s UNAIDS and the NIH-funded HPTN Ethics Working Group, Wakefield is passionate about implementation of evidence-based strategies to end the epidemic.

Michele Andrasik, PhD

Michele Andrasik, PhD, is the HVTN’s Director of Social and Behavioral Sciences and Community Engagement

Michele Andrasik is a clinical health psychologist. As the Director of Social and Behavioral Sciences and Community Engagement for the HVTN, Dr. Andrasik has led a robust Social and Behavioral Sciences research agenda for almost a decade. She has extensive experience working with communities and community organizations, both as a researcher and as a service provider. Prior to her doctoral training, Dr. Andrasik served as the Director of AIDS Services for a community-based HIV/AIDS service organization with offices in the New York City boroughs of Brooklyn and Manhattan. 

Dr. Andrasik’s research focus is on HIV prevention and social and structural factors implicated in health inequities. She brings her extensive expertise utilizing Community-Based Participatory Research (CBPR) and Qualitative Research Methods. Dr. Andrasik is also a Senior Staff Scientist in the Fred Hutchinson Vaccine and Infectious Disease Division and an Affiliate Assistant Professor in the Departments of Global Health and Environmental and Occupational Health Sciences at the University of Washington.

Stephaun Wallace, PhD

Stephaun Wallace, PhD, is the HVTN’s Social and Behavioral Sciences Junior Investigator Liaison

Stephaun Wallace is a research epidemiologist, thought leader, public speaker, and public health and business consultant. A nationally recognized public health/social justice leader, Dr. Wallace has more than 18 years of sexual/public health experience with diverse populations, including LGBTQ and MSM populations, and more than 22 years of grassroots social justice/community mobilization experience. Dr. Wallace views public health work through a social justice lens to understand how population-level health is impacted by structural and social factors like stigma, racism, sexism, historical trauma, and education and income inequalities.

As the Social and Behavioral Sciences Junior Investigator Liaison for the HVTN, Staff Scientist in the Vaccine and Infectious Disease Division at Fred Hutch, and a Clinical Assistant Professor in the Department of Global Health at the University of Washington, Dr. Wallace’s research commitment, inquiry, and interests sit at the intersection of public health and social justice, with a particular and intentional focus on the increasing the positive health outcomes of racial/ethnic, gender and sexual minority groups in the United States and internationally, as well as HIV prevention and treatment focused on key populations, including MSM and transgender persons. He conducts research that is accountable and responsive to key populations, that utilizes a population-centered approach and integrates the knowledge, assets, and strengths of the community into the research.